By Ben Glickman
NRx Pharmaceuticals on Thursday named Richard Narido interim chief financial officer.
The Radnor, Pa.-based biopharmaceutical company said that former CFO Seth Van Voorhees had resigned on Sept. 11 to pursue other professional opportunities. He will depart effective Sept. 30.
NRx said that Narido’s appointment was connected with a consulting services agreement with a division of LifeSci Advisors. The firm was involved in arranging for Narido to join as interim CFO.
Narido previously served as CFO of Lucira Health until the company was acquired by Pfizer in April 2023. He held various roles at Assembly Biosciences from July 2018 to March 2021, including executive director for finance, controllership and treasury.
Write to Ben Glickman at [email protected]
Read the full article here